Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2022 | $21.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $14.00 | Buy | HC Wainwright & Co. |
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00
HC Wainwright & Co. initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $14.00
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis.
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter
Nuvectis Pharma (NASDAQ:NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in non-small cell lung cancer (NSCLC) cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib and lorlatinib, showcasing NXP900's potential to address resistance mechanisms in NSCLC. Also, with the growing anticipation of the data update from NXP800 expected soon from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, Nuvectis is positioning itself at the forefron
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.40) by 37.5 percent. This is a 7.41 percent increase over losses of $(0.27) per share from the same period last year.
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTMSingle Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in AlecensaTMFort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved fo